This activity was originally broadcast live as a satellite symposium held in conjunction with the 2022 AMCP Annual Meeting.
Program Description
Ovarian cancer is the leading cause of death from gynecologic cancer in the United States. However, in recent years, the development and use of targeted therapies such as PARP inhibitors has contributed to a decreased mortality rate of women with ovarian cancer by about 2% per year. Despite the efficacy of PARP inhibitors, managed care pharmacists must consider several important points regarding their use in ovarian cancer prior to initiation of therapy including genetic testing. This activity will examine unique properties of PARP inhibitors currently approved for ovarian cancer treatment as well as those that are investigational, including line of therapy, BRCA mutation status, adverse effect management, and dosing and administration requirements. Additional evidence-based considerations for approaches to develop and implement oncology clinical pathways to improve delivery of care and manage costs associated with PARP inhibitor therapy for patients with ovarian cancer will be examined to equip managed care professionals to promote optimal medication utilization.
Target Audience: Managed care pharmacists, specialty pharmacists, health-system pharmacists, and oncology pharmacists
Type of Activity: Application
Release date: April 22, 2022
Expiration date: April 22, 2023
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify emerging trends in the clinical use of PARP inhibitors for the treatment of ovarian cancer.
- Explain how the recent trends in use of PARP inhibitors will impact the cost of caring for patients with ovarian cancer.
- Apply value-based approaches to care to the clinical data supporting the use of PARP inhibitor therapy to optimize the treatment of patients with ovarian cancer.
Rachel Justus, PharmD, BCPS, BCOP
Clinical Pharmacist Gynecologic Oncology
Novant Health Cancer Institute
Winston-Salem, North Carolina
Laura R. Bobolts, PharmD, BCOP
SVP, Clinical Strategy and Growth
OncoHealth
Plantation, Florida
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-200-H01-P. The activity is available for CE credit through April 22, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Rachel Justus, PharmD, BCPS, BCOP, and Laura Bobolts, PharmD, BCOP, have no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff— Jim Palatine, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA; Karleen Melody, PharmD; Crissy Wilson; Susan Pordon; Chloe Taccetta; and Brianna Winters have no financial relationships with commercial interests to disclose.
An anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
The content of this activity may include information regarding the use of products that may be inconsistent with, or outside the approved labeling for, these products in the United States. Pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult the prescribing information for these products.
The information discussed here represents the views of Rachel Justus, PharmD, BCPS, BCOP, and does not necessarily reflect the views of Novant Health.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms